MHRA April 2018

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/701831/DSU-April-2018-PDF.pdf

The valproate risks have already been looked at and specialists contacted and patients advised.

New guidance

https://www.gov.uk/guidance/valproate-use-by-women-and-girls

Ocaliva is not used by the practice.

Comments are closed.